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Protein–protein interactionThe protein DLK2, highly homologous to DLK1, belongs to the EGF-like family of membrane proteins, which
includes NOTCH receptors and their DSL-ligands. The molecular mechanisms by which DLK proteins regulate
cell differentiation and proliferation processes are not fully established yet. In previous reports, we
demonstrated that DLK1 interacts with itself and with speciﬁc EGF-like repeats of the NOTCH1 extracellular
region involved in the binding to NOTCH1 canonical ligands. Moreover, the interaction of DLK1 with NOTCH1
caused an inhibition of basal NOTCH signaling in preadipocytes and mesenchymal multipotent cells. In this
work, we demonstrate, for the ﬁrst time, that DLK2 interacts with itself, with DLK1, and with the same
NOTCH1 receptor region as DLK1 does. We demonstrate also that the interaction of DLK2 with NOTCH1
similarly results in an inhibition of NOTCH signaling in preadipocytes and Mouse Embryo ﬁbloblasts. In
addition, we demonstrate that a membrane DLK1 variant, lacking the sequence recognized by the protease
TACE, also inhibits NOTCH signaling. Furthermore, both DLK1 and DLK2 are able to decrease NOTCH activity
also when triggered by speciﬁc NOTCH ligands. However, the decrease in NOTCH signaling induced
by overexpression of Dlk2 is reversed by the overexpression of Dlk1, and viceversa. We conclude that DLK1
and DLK2 act as inhibitory non-canonical protein ligands for the NOTCH1 receptor that modulate NOTCH
signaling.; fax: +34 967599327.
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this work.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The Dlk1 gene encodes for DLK1, a transmembrane protein
belonging to the EGF-like family of proteins, which includes NOTCH
receptors and their ligands. DLK1 possesses a short intracellular
region, a transmembrane domain and an extracellular region with six
EGF-like repeats and a Tumor Necrosis Factor α-Converting Enzyme
(TACE) protease-sensitive target sequence. Accumulated evidence
suggests that Dlk1 is involved in several differentiation processes,
including differentiation of hepatocytes [1], hematopoiesis [2–8],
neuroendocrine differentiation [9], osteogenesis [10] and adipogen-
esis [3,11–14]. Regarding this last differentiation process, Dlk1 has
been shown either to inhibit or to enhance adipogenesis [15], and it is
also involved in the regulation of cell growth and cancer [16–21].
Finally, Dlk1 has been involved in the process of wound healing [22].The new discovered gene Dlk2 has appeared as a new player in the
complex biological processes modulated by Dlk1 [23]. The high degree
of homology between the proteins DLK1 and DLK2, particularly at
their EGF-like extracellular regions, suggested that, to some extent,
DLK2 might compensate for the absence of DLK1 or, perhaps, in some
situations, it might antagonize the activity of DLK1. Dlk2 expression is
detected in several mouse embryonic and adult tissues and cell lines,
and it shows a different, sometimes completely opposite, pattern of
expression from Dlk1 [23]. For instance, Dlk2 expression is absent
from liver during the ﬁrst days of life, when Dlk1 expression is
elevated, but increases around the 16th day of life, when Dlk1 ex-
pression starts to decline.
As it is the case for Dlk1, Dlk2 also participates in the regulation
of adipogenesis of 3T3-L1 and C3H10T1/2 cells, but it does so in a
manner other than Dlk1 [23]. Dlk1 overexpression inhibits the
adipogenesis of 3T3-L1 cells, but activates that of C3H10T1/2 cells;
and forced Dlk1 down-regulation activates 3T3-L1 adipogenesis, but it
exerts little effect on C3H10T1/2 adipose conversion. On the other
hand, Dlk2 down-regulation inhibits 3T3-L1 adipogenesis, but
activates that of C3H10T1/2 cells. Interestingly, these different actions
of Dlk1 and Dlk2 on adipogenesis correlate with the different basal
expression levels of both proteins in 3T3-L1 and C3H10T1/2 cells.
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tenfold than that of C3H10T1/2 cells, the latter express around four
times more Dlk2 mRNA than 3T3-L1 cells [23].
Recent data indicate that Dlk1 and Dlk2 gene expression could be
reciprocally regulated [15,23]. Transient transfection of C3H10T1/2 cells
with a Dlk1 siRNA caused a drastic decrease in Dlk1 expression, which
induced a substantial increase in Dlk2 expression levels. In addition,
stably transfected C3H10T1/2 cells with an antisense Dlk2 expression
construct resulted in adecreaseofDlk2 expression,whichwasassociated
with an increase ofDlk1expression levels.Moreover, the increase inDlk2
expression levels generated by transfection with a Dlk2 expression
construct associated with decreased Dlk1 expression in both 3T3-L1 and
C3H10T1/2 cell lines. Finally, the increase of Dlk1 expression that takes
place during extended time under conﬂuent culture conditions was
coincident with a concomitant decrease in Dlk2 expression in both cell
lines. Taken together, these results suggested that Dlk1 and Dlk2 may
both participate in a coordinated mechanism modulating cellular dif-
ferentiation and proliferation decisions in response to external signals.
The mechanism by which DLK1 and DLK2 exert these effects on the
control of adipogenesis or other differentiation and proliferation
processes has not been fully elucidated yet. It has been reported that
the mechanism of DLK1 action may involve interactions with other
molecules leading to modulation of proliferation and differentiation
signals [24–28]. Thus, DLK1 modulates the kinetics and activation level
of ERK1/2 MAPK triggered by Insulin/IGF-I (Insulin Growth Factor-I)
[28]. It has been also demonstrated that binding of DLK1 to IGFBP1/IGFI
complexes favors the release of IGF-I near its receptor, which increases
the adipogenic potential of 3T3-L1 cells. These results suggest that
membrane DLK1 variants are necessary for the induction of adipogen-
esis in response to IGF-I [27]. DLK1 also interacts with itself through its
EGF-like repeat region, an interaction that would allow soluble DLK1
variants, generated by the action of the protease TACE [29], tomodulate
DLK1–DLK1 membrane interactions, potentially important for its
function [25]. Finally, an increasing body of evidence strongly indicates
that DLK1, despite lacking the DSL (DELTA, SERRATE, and LAG-2)
domain, characteristic of NOTCH ligands, interacts also with NOTCH1
and acts as a negative regulator of NOTCH signaling [15,26,30].
The proteins of the NOTCH receptor and ligand family interact with
each other through their EGF-like repeats and are implicated in cell fate
determination of numerous cell types, inﬂuencing a wide variety of
developmental and differentiation processes [31–38]. The interaction of
speciﬁc EGF-like sequences of the four different mammalian NOTCH
receptors (NOTCH1-4) with the DSL domain of the ligands [DELTA-like
(DLL)-1, -3 and -4, and JAGGED-1 and -2] [31,32,34–36,39–43] leads to
the liberation of an active NOTCH intracellular domain (NICD) from the
plasma membrane [44–49]. The released NICD translocates to the
nucleus and binds to CSL (CBF-1, Suppressor of hairless, LAG-1)/RBP-Jk
and Mastermind (MAML) factors, which forms part of a transcriptional
activator complex. This complex activates the expression of several
genes, such as theHes andHey transcription factors, whichmodulate, in
turn, the expression of many other cell differentiation and proliferation
genes [50–52].
The high homology between DLK1 and DLK2 strongly suggested
that DLK2 could also interact with NOTCH1 and modulate its ac-
tivation. In this work, we demonstrate by several approaches that,
indeed, DLK2 interacts with the same NOTCH1 region as DLK1 does,
and inhibits NOTCH signaling in preadipocytes and Mouse Embrion-
ary Fibroblasts (MEFs). Moreover, we demonstrate here that DLK1
and DLK2 proteins interact with themselves and with each other. The
interaction between DLK1 and DLK2 seems to lead to a reciprocal
inhibition of each other's activities, resulting in greater levels of
NOTCH signaling. In addition, we demonstrate here that DLK proteins
compete with DLL4 and JAGGED1 ligands' ability to trigger NOTCH
signaling, which, in turn, modulates the level of NOTCH activation.
Finally, we also have observed that a membrane-bound variant of
DLK1, lacking the protease-sensitive region, inhibits NOTCH signalingas well, suggesting that membrane DLK1 variants also act as NOTCH
inhibitors. We propose here that DLK proteins may regulate adi-
pogenesis and other differentiation processes by functioning as in-
hibitory non-canonical ligands of NOTCH signaling that reciprocally
modulate each other's activities.
2. Materials and methods
2.1. Bacterial procedures and yeast two-hybrid analysis
TOP10 Escherichia coli competent cells were used for transformation
and plasmid ampliﬁcation, following the manufacturer's recommenda-
tions (Gibco BRL, Rockville, MD, USA). For bacterial culture, liquid or
solid LBmediawere supplementedwith 100 μg/ml of ampicillin (Sigma,
Saint Louis, MO, USA). Plasmid DNA was isolated and puriﬁed by using
the GenElute Plasmid Miniprep Kit (Sigma, Saint Louis, MO, USA) and
ionic exchange columns (Qiagen Inc., Hilden, Germany), according to
the manufacturer's directions.
Saccharomyces cerevisiaeCG1945 yeast strainwasused for yeast two-
hybrid assays, following manufacturer's protocols (Clontech, Mountain
View, CA, USA). Co-transformationswith the different plasmid combina-
tions were done with 1 μg of each individual plasmid. Transformed
colonies were selected in a minimal medium lacking Leucine and
Tryptophan (MM-LT). To search for potential protein–protein interac-
tions, selected colonies that had grown in MM-LT medium were grown
again in a minimal medium lacking Histidine, Leucine and Tryptophan
(MM-LTH),with increasingconcentrations of 3-Amino-1, 2, 4-Triazol (3-
AT), ranging from 0 to 100mM [25,26]. These assays were repeated at
least three times.
The Dlk1 and Notch1 yeast expression constructs used were pre-
viously described [25,26]. In-frame DLK2-GAL4 binding (BD) or ac-
tivation (AD) domain fusion protein expression constructs weremade
to express different DLK2 protein regions.We ampliﬁed by RT-PCR the
appropriate Dlk2 cDNA fragments (ATCC clone: ID 4913786) and
cloned them into the EcoRI-BamHI sites of the pAS2-1 vector, or into
the EcoRI-XhoI sites of the pACT2 vector (both vectors from Clontech,
Mountain View, CA, USA). The cDNA encoding for the entire DLK2
protein, lacking its signal peptide region, to be cloned into pAS2-1
(pASDLK2), was ampliﬁed with primers DLK2-pAS2-1up: 5′-ATG GGG
GAA TTC ATC CTG GGG GCA ACC AGC CAG-3′, and DLK2-pAS2-1low:
5′-ATG GGG GGA TCC GTT AAG GTA GCT AGA AAG GCT CCT CCC A-3′.
The cDNA encoding for the same protein as above, to be cloned in
pACT2 (pACDLK2), was ampliﬁed with primers DLK2-pACT2up: 5′-
ATG GGG GAA TTC GAA TCC TGG GGG CAA CCA GCC AG-3′, and DLK2-
pACT2low: 5′-ATG GGG CTC GAG GTT AAG GTA GCT AGA AAG GCT
CCT CCC A-3′. The cDNA region encoding for the six DLK2 EGF-like
repeats, to be cloned into pAS2-1 (pASDLK2E), was ampliﬁed with
primers DLK2-pAS2-1up (indicated above) and DLK2EGFs-pAS2-
1low: 5′-ATG GGG GGA TCC GTT AAG GCT CTG GAG CAG GTA GGA
C-3′. The same Dlk2 cDNA encoding for the EGF-like region, to be
cloned into pACT2 (pACDLK2E), was ampliﬁed with primers DLK2-
pACT2up (indicated above) and DLK2EGFs-pACT2low: 5′-ATG GGG
CTC GAG GTT AAG GCT CTG GAG CAG GTA GGA C-3′. The Dlk2 cDNA
encoding for the intracellular DLK2 region, to be cloned into pAS2-1
(pASDLK2I), was ampliﬁed with primers DLK2int-pAS2-1up: 5′-ATG
GGG GAA TTC CTG ACC CTG AGG GCA TGG CGC-3′, and DLK2-pAS2-
1low (indicated above). The same Dlk2 cDNA region to be cloned into
pACT2 (pACDLK2I) was ampliﬁedwith primers DLK2int-pACT2up: 5′-
ATG AGG GAA TTC TAC TGA CCC TGA GGG CAT GGC GCC GA-3′, and
DLK2-pACT2low (indicated above).
2.2. Mammalian plasmids
Plasmids pLNDLK2-MYC and pLNDLK2aS contain the complete
cDNA sequence of Dlk2 cloned into the pLNCX2-MYC vector, in sense
or antisense orientation, respectively [23]PlasmidspCDLK1 andpCDLK2
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either ofDlk1orDlk2 in sense orientation, respectively [23]. The plasmid
pLNDLK2E-MYC contains the cDNA encoding for the extracellular
region of DLK2, fused to the epitope c-MYC at its C-terminal end, cloned
into the HindIII and SalI restriction sites of vector pLNCX2-MYC. The
extracellular Dlk2 cDNA sequence was ampliﬁed with DLK2HindIII1U
(5′-ACT CAA GCT TTC GGC TGG CAT GGC AGC TACT-3′), and
DLK2SalI989L (5′-TGA TGT CGA CAA CTA CAG CTG AGG TGG GCA T-
3′) primers.
To generate a C-terminal endHA epitope in vector pLHCX (Clontech,
Mountain View, CA, USA), we used a standard annealing of the phos-
phorylated oligonucleotides HAlinker-up: 5′-GGC CGC GGA TCC TAC
CCA TAC GAT GTT CCA GAT TAC GCT TAA AT-3′, and HAlinker-low: 5′-
CGA TTT AAG CGT AAT CTG GAA CAT CGT ATG GGT AGG ATC CGC-3′.
TheseoligonucleotidespossessNotI orClaI overhangs, respectively. Both
oligonucleotides possess a BamHI restriction site,whichwas convenient
to determine the insert orientation, and a TAA stop codon. The DNA
fragment thus generated was cloned into the ClaI and NotI restriction
sites of pLHCXandpLPCXvectors (Clontech,MountainView,CA,USA) to
produce the pLHCX-HA and pLPCX-HA vectors, respectively.
pLHDLK1-HA expresses the entire DLK1 protein fused to HA epitope
at its C-terminal end. The complete cDNA of Dlk1 was ampliﬁed with
oligonucleotides DLK1m1267LBamHI: 5′-CAA TGG ATC CGA TCT CCT
CAT CAC CAG CCT C-3′, and DLK1m55UEcoRI: 5′-ATA CGA ATT CAA CCA
GAAGCCCAG CGC ACGC-3′, by using plasmid p23B1 as a template [16].
This full length Dlk1 cDNA was ﬁrst cloned into the BamHI and EcoRI
restriction sites of pLPCX vector. The resulting plasmid was digested
with BamHI and HindIII restriction enzymes and the DNA fragment
containingDlk1 cDNAwas cloned into the BamHI andHindIII restriction
sites of the vector pLHCX-HA. pLHDLK1E-HA expresses the extracellular
region of DLK1 fused to the HA epitope at its C-terminal end. The cDNA
corresponding to this DLK1 region was ampliﬁed with the primers
DLK1m949LBamHI: 5′-TAA TAT GGA TCC AAC AGG CAG CTC GTG CAC
CCC-3′, and DLK1m55UHindIII: 5′-ATT CAA GCT TAA CCAGAAGCC CAG
CGC AGC C-3′. The ampliﬁed cDNA fragmentwas cloned into the BamHI
and HindIII restriction sites of pLHCX-HA. pLHDLK1ΔP-HA plasmid
contains the cDNA of Dlk1 lacking the region encoding the protease
target fragment and fused in framewith theHAepitope at its C-terminal
end. To make this construct, we PCR-ampliﬁed the 5′ region of Dlk1
cDNA with the primers mDLK1U28: 5′-GTG CAA CCC TGG CTT TCT TCC
CGC TGG A-3′, and mDLK1932L39: 5′-AAC AGG CAG CTC GTG CAC CCC
GGGGGT CAG GCGGTA GGT-3′. We also PCR-ampliﬁed the 3′ region of
Dlk1 cDNA with the primers mDLK11043U45: 5′-CCC GGG GTG CAC
GAG CTG CCT GTT CCT CTC CTC ACC GAG GGA CAG-3′, and
mDLK1394L30: 5′-ATT CCA CAC AAT AGA GCA AAC TCC ACC ACA-3′.
We next ampliﬁed the internally deleted Dlk1 cDNA fragment with the
primers mDlk1U28 and mDlk1394L30, digested the PCR product with
MscI andNheI, and cloned the puriﬁedDNA fragment into theMscI–NheI
sites of plasmid pBluescript SK− [16]. The resulting construct, contain-
ing the full lengthDlk1 cDNAwith an internal deletion corresponding to
the protease-sensitive regionwas used as a template to amplify Dlk1ΔP
with primers DLK1m127UHindIII: 5′-AGC CAA GCT TCC GAG ATG ATC
GCG ACC G-3′, and DLK1m1267LBamHI: 5′-CAA TGG ATC CGA TCT CCT
CAT CAC CAG CCT C-3′. The ampliﬁed fragment was ﬁnally cloned
between the BamHI and HindIII restriction sites of pLHCX-HA vector to
generate the plasmid pLHDLK1ΔP-HA.
We also generated a C-terminal end 6×HIS epitope by a standard
annealing of the phosphorylated oligonucleotides 6×HISUp: 5′-GAT
CCG GGC CCC ACC ACC ACC ACC ACC ACA-3′, and 6×HISLow: 5′-GAT
CTG TGG TGG TGG TGG TGG TGG GGC CCG-3′. pLPCX-6HIS-HA vector
was generated by cloning the double strand DNA fragment generated
into theBamHI restriction site of pLPCX-HA. PlasmidspLPDLK1E-6×HIS-
HA and pLPDLK2E-6×HIS-HA were generated by inserting the
corresponding ampliﬁed cDNA fragments into pLPCX-6×HIS-HA vector.
The cDNA encoding for the extracellular region of DLK1 was ampliﬁed
from plasmid 23B1 [16], by using the primers DLK1e55UEcoRI: 5′-ATACGA ATT CAA CCA GAA GCC CAG CGC ACG C-3′, and DLK1949LBamHI:
5′-TAA TAT GGA TCC AAC AGG CAG CTC GTG CAC CCC-3′. The cDNA
encoding for the extracellular region of DLK2was ampliﬁed byusing the
primers DLK2UHindIII: 5′-GCC GCG AAG CTT CAT CCG TCC GTC CCT CCT
GA-3′, and DLK2LBamHI: 5′-GCC TAG GGA TCC AGC AGG TAG GAC AAG
TTC ACA AGT CTT ACC ACC-3′. Plasmids pLPD4E-6×HIS-HA and pLPJ1E-
6×HIS-HA derivate also from vector pLPCX-6×HIS-HA, and contain
each the cDNA encoding for the extracellular region of DLL4 (cloned
into EcoRI and BamHI restriction sites), or JAGGED1 (cloned intoHindIII-
BamHI restriction sites), respectively, in frame with the carboxi-
terminal 6×HIS and HA epitopes at their C-terminal end. The cDNAs
fragments encoding for the extracellular regions of mouse DLL4 or
JAGGED1 were PCR-ampliﬁed from full-length cDNA clones ATCC
9859566 or ATCC 10699187, respectively. To amplify the extracellu-
lar-encoding region of Dll4 cDNA, we used the primers DLL4E-Up: 5′-
AAG GCG GAA TTC TTC GGA GTC CCG GAG TGG AGA GG-3′, and DLL4E-
Low: 5′-AAT TCG GGA TCC AGC TAC CCA GGG GAA GCT GGG TG-3′. To
amplify the extracellular-encoding region of Jagged1 cDNA, we used the
primers JAGGED1E-Up: 5′-AAT TAT AAG CTT CCC GTG GCG CGC GCA
GCG ATG-3′, and JAGGED1E-Low: 5′-CCG GCG GGA TCC ATC TGT TCT
GTT TTT CAG AGG ACG CC- 3′.
pNIC-1 plasmid contains 1,550 bp of the intracellular domain of
human Notch1 cDNA (NICD1500) [26,53]. The plasmids pLPN1 and pCN1
contain the complete cDNAsequenceofmouseNotch1 (ATCCclone:MBA-
105), cloned into the EcoRI restriction site of pLPCX or pCD2, respectively,
in the sense orientation. The plasmid p3×FLAG-N1 (10–15) contains the
cDNA region encoding for the EGFs 10 to 15 of mouse NOTCH1, fused to
three copies of the FLAG epitope at the N-terminal end. This region was
ampliﬁedwithprimersN1(10–15)UP(5′-ATTAAGCTTGGTGGTGGTTGC
GAATGTCCGCATGGGCGCACAGG-3′), andN1(10–15)LOW(5′-GCGCC
TCT AGA CTAGCA CTC ATT GAT GTT GGT CTC ACAGTG ATGGCC-3′), and
cloned into theHindIII and XbaI sites of the p3×FLAG-CMV-23 vector. The
plasmid P3×FLAG-CMV-23 was prepared from the p3×FLAG-MYC-CMV-
23 vector (Sigma, Saint Louis, MO, USA) by eliminating the sequence
corresponding to the MYC epitope. This epitope was eliminated by
digestion with BamHI and SmaI restriction enzymes, Klenow treatment
and re-ligation. The plasmid pLPJ1 contains the complete mouse Jagged1
cDNA sequence (ATCC clone 10699187), cloned into the NheI and BglII
restriction sites of the pLPCX vector. All the mammalian plasmids used in
this work are sumarized in supplementary table 1. One μg of DNA from
each plasmid constructed in this work was used for sequencing with the
“ABI PRISM dRhodamine Terminator Cycle Sequencing Ready Reaction
Kit” (Applied Biosystems, Carlsbad, CA, USA) or sent to Macrogen (Seoul,
South Corea) to conﬁrm the correct insertions and the absence of
mutations. The oligonucleotides used for cloning and sequencing were
designed and obtained from Bonsai Technologies (Madrid, Spain).
2.3. Mammalian cell culture, cell transfections and gene expression
assays
Mammalian cell lines were cultured at 37 °C, in a 5% CO2 humidiﬁed
atmosphere, in Dulbecco's modiﬁed Eagle's medium (DMEM; Life
technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum
(FBS). The cell lines used were: 3T3-L1 (ATCC CCL-92.1); HEK 293T/17
(ATCC CRL-11268); Balb/c 14, a clone obtained in our laboratory by
selecting for Balb/c 3T3 (clone A31, ATCC CCL 163) sub-clones negative
for Dlk1 expression [24,26]; and immortalized Dlk1+/+ and Dlk1−/−
MEFs, obtained from Dlk1 wild type or knockout [54] embryos,
respectively, at day 13.5 post-conception, as described by Todaro and
co-workers in 1963 [55]. Transient transfectionswere performed in 50%
conﬂuent cellswith1–10 μgof thedifferentplasmids, byusing Superfect
reagent (Qiagen Inc., Hilden, Germany), following the manufacturer's
recommendations. The Green Fluorescent Protein expression construct
pEGFP-N1 (Clontech, Mountain View, CA, USA) was used to determine
transfection efﬁciency. For mRNA gene expression analysis, conﬂuent
cell monolayers were washed twice with PBS and detached with
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collected by centrifugation (180×g, 5 min., 4°C) and washed twice
with PBS. Total RNA was isolated by using the Rneasy Kit (Qiagen Inc.,
Hilden, Germany). cDNAs were obtained by using a cDNA synthesis kit
(Fermentas, Madrid, Spain). To perform gene expression assays, total
cDNAs were used as templates in standard PCR experiments. The
primers and conditions used to determine Dlk1 and Dlk2 expression
levels were those used previously [12,26,28,56]. PCR products were
electrophoresed on 1% agarose gels and visualized by staining with
ethidium bromide. Expression of the gene encoding the phosphoribo-
protein P0, a well established expression and quality control [57], was
used as a standard in PCR assays.
2.4. Afﬁnity chromatography
HEK 293T/17 cells were transiently transfected with vector pLPCX-
6×HIS-HA, as a control, or with pLPD4E-6×HIS-HA, pLPJ1E-6×HIS-HA,
pLPDLK1E-6×HIS-HA, or pLPDLK2E-6×HIS-HA plasmids. Protein
expression was analyzed by Western blot of the cell culture super-
natants, by using an anti-HA antibody (Covance, Princeton, NJ, USA).
Culture supernatants from cells expressing JAGGED1E were ﬁltered
and concentrated with 100 kDa centricons (Millipore, billerica, MA,
USA) (100 ﬁltering). The rest of the culture supernatants were ﬁltered
with 100 kDa and then concentrated with 10 kDa centricons (100/10
ﬁltering). We also obtained control samples that were processed in
the same way. After ﬁltering and concentration, all the proteins and
controls were puriﬁed by using the Ni-NTA His Bind Resin (Novagen,
Darmstadt, Germany). The puriﬁed samples DLL4E-6×HIS-HA
(DLL4E-P); JAGGED1E-6×HIS-HA (JAGGED1E-P); DLK1E-6×HIS-HA
(DLK1E-P); DLK2E-6×HIS-HA (DLK2E-P); Control-P1 (100/10 ﬁlter-
ing); and Control-P2 (100 ﬁltering) were dialyzed and concentrated
with binding buffer (Novagen, Darmstadt, Germany) lacking imidaz-
ole. Protein concentration was determined by Elisa with an anti-HA
antibody, using known concentrations of a puriﬁed HA epitope (Alpha
Diagnostic International, San Antonio, Texas, USA).
2.5. Protein sample preparation, co-immunoprecipitation analysis and
Western blot
For general protein analysis, 48 h following transfection, cells were
resuspended in lysis buffer (50 mMTris–HCl pH 7.4; 1% Igepal; 150 mM
NaCl; 1 mMEDTA; 1 mMPMSF; 1 μg/ml Leupeptin andAprotinin;1 mM
Na3VO4; 1 mMNaF),maintained on ice for 30 min, and then centrifuged
at 10,000×g for 10 min at 4 °C. The soluble extractswere then collected,
and the protein concentrations were determined by using “Protein
Assay Dye Reagent” (BioRad, München, Germany), following the
manufacturer's recommendations. Ten to one hundred micrograms of
total protein extracts were loaded into 10–12% polyacrilamide gels.
Co-immunoprecipitations were carried out by incubating different
combinations of puriﬁed proteins or soluble cell extracts with α-
HA.11 (Covance, Princeton, NJ, USA) or α-FLAG-M2 (Sigma, Saint
Louis, MO, USA) antibodies (1:500 dilution in PBS buffer). HEK 293T/
17 soluble protein extracts, containing or not a NOTCH1 truncated
protein (3×FLAG-N1 (10–15)) or a DLK2-MYC fusion protein, were
mixed with puriﬁed DLK1E-P, DLK2E-P, JAGGED1E-P or their
corresponding controls (Control-P1 or Control-P2). Following over-
night incubation at 4 °C, protein A+G Agarose (Pierce, Rockford, IL,
USA) was added to the mixtures for 2 h at 4 °C. Then, complexes were
washed three times with cold PBS and resuspended in denaturing
sample buffer. Immunoprecipitation complexes were boiled and
loaded into 10–12% (w/v) polyacrylamide gels.
Westernblotwasperformedbyusinganappropriateddilution of the
primary and secondary antibodies. The primary antibodies were: a
rabbitα-mouse DLK11126 [27,58], which recognizes theDLK1EGF-like
region; a hamsterα-mouseNOTCH18 G10 (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA), which recognizes the extracellular region ofNOTCH1; a rabbit α-mouse NOTCH1 C20 (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA), which recognizes the intracellular region of
NOTCH1; a mouse α-c-MYC 9E10 (Santa Cruz Biotechnologies, Santa
Cruz, CA, USA); amouseα-FLAG-M2; amouseα-HA.11; and a rabbitα-
DLK2 antibody. The α-DLK2 antibody was generated in our laboratory
by immunization with two peptides from the DLK2 intracellular region
(QDQECQVSMLPAGK and DLPPEPGKTTALC) conjugated with KLH. The
immune serum was puriﬁed by afﬁnity chromatography against the
peptide DLPPEPGKTTALC. Finally, the activation of NOTCH1 (active
NICD) was analyzed in cells with different levels of DLK1 and DLK2
proteins, by using the “Cleaved NOTCH1 (Val 1744)” antibody (Cell
Signaling, Beverly, MA, USA). Densitometric analyses of Western blot
signalsweremadebyusingQuantityOne1-Danalysis software (BioRad,
München, Germany). Detection of α-tubulin with a speciﬁc antibody
(Sigma, Saint Louis, MO, USA) was used as the protein loading control.
2.6. Luciferase assays
The NOTCH transcriptional activity was analyzed by luciferase
assays in Balb/c 14, HEK 293T/17, 3T3-L1 and immortalized Dlk1−/−
MEFs cells. Most of the luciferase assays were performed in Balb/c 14
cells due to its high transfection efﬁciency compared to the other cell
lines. These cells were transfected with pGLucWT (a plasmid expres-
sing the luciferase gene under a promoter that contains binding sites for
CSL/CBF-1/RBP-J factor, [26]) and combinations of the expression
plasmids under study. Depending on the assay, transfected cells were
incubated in the presence of Control-P1, DLK1E-P or DLK2E-P proteins.
To normalize the data obtained, cells were also transfected with pRLTK
(renilla expression plasmid, Promega, Madison, WI, USA).
Alternatively, twenty-four well plates were incubated overnight at
4 °Cwith anti-HAantibody, diluted 1:500 in coating buffer (eBioscience,
San Diego, CA, USA). Wells were then blocked with DMEM 10% FBS for
1 h at 37 °C, and they were incubated another extra hour at 37 °C with
50 ng of Control-P1 or DLL4E-P proteins. 293T/17 cells, previously
transfected with pGLucWT luciferase construct and pRLTK for 24 h,
were added to the wells and incubated in the presence of Control-P1,
DLK1E-P or DLK2E-P proteins, for another 24 h.
In all these luciferase assays, cells were lysed and processed using
the dual luciferase Kit (Dual-Luciferase Reporter Assay System,
Promega, Madison, WI, USA) 24–48 h after transfection. Experiments
were repeated at least three times. Statistical analysis of the data was
performed to calculate the means and S.E.M. Data were also analyzed
by Anova test to determine statistical signiﬁcance.
3. Results
3.1. The protein DLK2 interacts with itself, with DLK1, and with NOTCH1
The high homology between the proteins DLK1 and DLK2, and the
previous data demonstrating that DLK1 interacts with itself and with
NOTCH1, suggested that DLK2 could also interact with NOTCH1 and,
perhaps, with itself and with DLK1, generating homodimers and
heterodimers, which could be very important for the function of the
DLK proteins. To identify these potential interactions, we performed a
3-AT assay by using the Saccharomyces cerevisiae “GAL4 two-hybrid
system” (Fig. 1). Yeast cells were co-transformed with plasmids
expressing fusion proteins of the GAL4 transcription factor with
different regions of mouse DLK1, DLK2 or NOTCH1 proteins (see
Materials and methods), and co-transformant colonies were analyzed
by 3-AT assays. Co-transformant colonies with the plasmids pVA3-1,
expressing p53; and pTD1-1, expressing the T antigen, were used as a
positive control for protein–protein interactions. Co-transformant
colonies with the plasmids pLAM5′-1 and pTD1-1, or the empty
plasmids, pAS2-1 and pACT2, were used as negative controls.
As shown in Fig. 1, we detected a strong interaction of DLK2 with
itself (20 to 50 mM3-AT), andbetweenDLK1andDLK2 (up to 5–10 mM
Fig. 1. The protein DLK2 interacts with itself, with DLK1 and with NOTCH1 in the yeast
GAL4 two-hybrid system. Yeast cells were co-transformed with pAS2.1- or pACT2-
derived plasmids containing cDNAs driving the expression of different regions of DLK1,
DLK2 or NOTCH1 proteins, fused at the amino terminal end to GAL4 BD or AD DNAs. The
ﬁgure shows the growth of co-transformed colonies on a solid minimal medium lacking
Leucine and Tryptophan (MM-LT) or lacking Leucine, Tryptophan and Histidin, but
containing 3-Amino Triazol (MM-LTH+3-AT) at concentrations ranging from 0 to
100 mM, which allows an estimate of the relative strength of the protein interactions.
Dlk1 and Dlk2: complete cDNAs encoding the corresponding proteins lacking their
signal peptides. Dlk1E and Dlk2E: cDNAs encoding for the extracellular regions of these
proteins lacking their signal peptides. Dlk1I and Dlk2I: cDNAs encoding for the
intracellular regions of these proteins. N1 (X-Y): cDNAs encoding for EGFs X to Y of
NOTCH1. Co-transformants of pVA3-1 (p53) and pTD1-1 (T antigen) plasmids were
used as a positive control of protein-protein interaction. Co-transformants of pLAM5′-1
(Laminin C) and pTD1-1 plasmids, or pAS2-1 and pACT2 empty vectors, were used as
negative controls. Experiments were repeated at least three times.
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These interactions suggest the generation of homodimers and hetero-
dimers between these two proteins. However, we did not detect any
interaction between the intracellular regions of DLK1 and DLK2,
indicating that these proteins interact only through their extracellular
EGF-like regions. On the other hand, we detected a strong interaction
betweenwhole DLK2 and the EGFs 12 and 13 of NOTCH1 (up to 50 mM
3-AT), butwe didnot detect any interaction betweenDLK2and theEGFs
10 and 11, or 13 and 14 of NOTCH1. Moreover, we did not detect any
interaction between theEGFs 12 and 13 ofNOTCH1and the intracellular
region of DLK2. These results suggest that, as it happens with DLK1, the
extracellular region of DLK2 speciﬁcally interacts with the NOTCH1
receptor region involved in the binding to canonical ligands [26].
The interactions of DLK2 with itself, with DLK1 and with NOTCH1
in the yeast two-hibrid system were conﬁrmed by co-immunopre-
cipitation (Fig. 2). For the co-immunoprecipitation assays, we mixed
soluble extracts from HEK 293T/17 cells overexpressing the 3×FLAG-
N1 (10–15) protein, or the DLK2-MYC protein (Fig. 2A), with the
puriﬁed soluble proteins DLK1E-P, DLK2E-P or JAGGED1E-P (Fig. 2B).
Co-immunoprecipitation of DLK2 and NOTCH1 proteins was achieved
by adding an α-FLAG-M2 antibody to a mixture of DLK2E-P and
soluble extracts from HEK 293T/17 cells overexpressing 3×FLAG-N1
(10–15) (Fig. 2C). For co-immunoprecipitation of DLK1 and DLK2
proteins, we used anα-HA.11 antibody added to amixture of DLK1E-P
and soluble extracts from HEK 293T/17 cells overexpressing DLK2-
MYC (Fig. 2D). The co-immunoprecipitation of NOTCH1 and JAGGED1
proteins was used as a positive control, and it was carried out with an
α-FLAG-M2 antibody added to a mixture of JAGGED1E-P and soluble
extracts from HEK 293T/17 cells overexpressing 3×FLAG-N1 (10–15)
(Fig. 2E). We also performed immunoprecipitations of negative
controls by using soluble extracts from HEK 293-T/17 cells that had
been transfected with p3×FLAG-CMV-23 (FLAG Vector) or pLNCX2-MYC (MYC Vector) empty vectors, or by using Control-P1 and
Control-P2 samples. In addition, we controlled for a potential non-
speciﬁc protein binding to the agarose resin by performing the same
immunoprecipitation protocol without the addition of antibodies. The
proteins did not bind non-speciﬁcally to the resin (data not shown).
As expected, JAGGED1 co-immunoprecipitated with NOTCH1, and we
conﬁrmed that DLK2 interacts with DLK1 and with NOTCH1. Finally,
we also investigated whether or not DLK proteins could interact with
some NOTCH ligands thus preventing them from reaching and
interacting with their receptor. In this round of experiments, we did
not observe DLK1 or DLK2 co-immunoprecipitatation with DLL4 or
JAGGED1 (data not shown), which suggest that both DLK proteins
interact with NOTCH1, but not with its ligands.
3.2. DLK1 and DLK2 inhibit NOTCH activation and signaling
Considering that DLK1 has been reported to function as a NOTCH
signaling inhibitor [15,26,30], we decided to explore whether this
possibility alsooccurredwithDLK2. Toget anadequate in vitro system to
design andperform functional experiments,we analyzed theexpression
of the genes Dlk1 and Dlk2, by standard RT-PCR, in Balb/c 14 and 3T3-L1
cell lines, and in immortalizedDlk1−/−MEFs. As expected, 3T3-L1 cells
expressedDlk1 andDlk2, and Balb/c 14 cells and immortalizedDlk1−/−
MEFs did not express Dlk1, but expressed detectable levels of Dlk2
(Fig. 3A).We also analyzed NOTCH transcriptional activity by luciferase
assays to demonstrate that these cell lines express all the necessary
components driving NOTCH-dependent gene expression (Fig. 3B, C and
D). All cell lines were co-transfected with the NOTCH-responsive
reporter plasmid pGLucWT and plasmid pLNCX2 (Control) or with
plasmid pNIC-1 (human NICD1500). As shown in Fig. 3B, C and D, the
three cell lines studied were able to signiﬁcantly increase the luciferase
activity in response to the overexpression of the constitutively active
human NOTCH1 intracellular domain (NICD1500).
To investigate whether the detected protein–protein interactions had
any functional implications on NOTCH signaling, we analyzed NOTCH-
dependent transcriptional activity in Balb/c 14 cells by luciferase assays.
Balb/c 14 cells were co-transfected with pGLucWT and one of the
plasmids driving the expression of the indicated proteins (Fig. 3E and F).
Transfection with plasmids driving the expression of the entire or the
extracellular DLK2 protein variants resulted in the inhibition of NOTCH
signaling (Fig. 3E). Moreover, background NOTCH signaling was slightly
increasedwhen the cellswere transfectedwith a construct expressing the
complete cDNA of Dlk2 in antisense orientation [23], conﬁrming the
inhibitory effect of Dlk2 on NOTCH signaling. On the other hand,
endogenous NOTCH activity was inhibited when different versions of
DLK1, all of them containing the six EGF-like repeats of its extracellular
region, including the membrane bound DLK1 variant (DLK1ΔP), were
overexpressed in these cells (Fig. 3F). These results demonstrate that both
DLKproteinsareable to inhibitNOTCHsignaling, including themembrane
bound variant of DLK1, which caused the greatest level of inhibition.
If DLK proteins are able to inhibit NOTCH signaling, they should
probably diminish the amount of intracellular active NOTCH1 (active
NICD). To explore this possibility, we used Dlk1+/+ and Dlk1 −/−
MEFs, and transiently transfected 3T3-L1 cells to express higher levels
of DLK1 or DLK2 than control cells. We analyzed the level of
endogenous active NOTCH1 intracellular region (active NICD) by
Western blot in these cells (Fig. 4A, B, and C). As a positive control, we
analyzed the levels of active NICD in transiently-transfected 3T3-L1
cells with plasmid pCN1, which expresses the entire NOTCH1 protein
(Fig. 4D). As a negative control, we determined the endogenous
NOTCH activation in 3T3-L1 control cells treated for 48 h with 10 μM
of the γ-secretase inhibitor DAPT, which inhibits NOTCH signaling
(Fig. 4E). As shown in Fig. 4C, Dlk1−/−MEFs showed higher levels of
active NICD than wild-type MEFs. On the other hand, transient 3T3-L1
transfectants, expressing higher levels of DLK1 or DLK2, displayed
lower levels of active NICD than control cells transfected with the
Fig. 2. DLK2 co-immunoprecipitates with DLK1 and with NOTCH1. A. Western blot analysis of soluble total extracts from HEK 293T/17 cells transfected with pFLAG-N1 (10–15) or
pLNDLK2-MYC plasmids. FLAG Vector SE and FLAG-N1 (10–15) SE: soluble cell extracts from KEK 293T/17 cells transfected with the empty vector or the same vector expressing the
EGF-like repeats 10 to15 of NOTCH1 fused to the FLAG epitope at the N-terminal end, respectively. MYC Vector SE and DLK2MYC SE: soluble cell extracts from HEK 293T/17 cells
transfected with the empty vector or the same vector expressing the entire DLK2 protein fused to the MYC epitope, respectively. B. Western blot analysis of soluble DLK proteins
[DLK1E-P (DLK1E-6×HIS-HA) and DLK2E-P (DLK2E-6×HIS-HA)] and soluble ligand JAGGED1 [JAGGED1E-P (JAGGED1E-6×HIS-HA)], puriﬁed from culture supernatants from HEK
293T/17 transient transfectants. Control-P1 and Control-P2: puriﬁed culture supernatants from HEK 293T/17 cells transfected with pLPCX6HIS-HA empty vector. C. Western blot
analysis of the co-immunoprecipitation of DLK2 and NOTCH1 proteins. D.Western blot analysis of the co-immunoprecipitation of DLK1 and DLK2 proteins. E.Western blot analysis of
the co-immunoprecipitation of NOTCH1 and JAGGED1 proteins, used as a positive control of the assays. Immunoprecipitations (IP) andWestern blots (WB) were performed with the
antibodies indicated (see Materials and methods). M: molecular weight markers (KDa).
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are able to inhibit NOTCH activity and signaling by decreasing the
amount of active NOTCH1 intracellular domain.
3.3. The interaction between DLK1 and DLK2 and their competition with
the NOTCH ligands DLL4 and JAGGED1 modulate NOTCH signaling
The fact that DLK1 and DLK2 extracellular regions appear to interact
with the same EGF-like NOTCH1 region as the canonical ligands do,
suggested that DLKproteins could competewith these ligands for NOTCH
binding. To investigate this possibility, we analyzed the NOTCH
transcriptional activity after ligand triggering in the presence of DLK1 or
DLK2 soluble proteins Todo that,weﬁrst analyzedNOTCH transcriptionalactivity in Balb/c 14 cells transiently co-transfected with pGLucWT and a
vector overexpressing the complete cDNA of Jagged1 (pLPJ1) or Notch1
(pLPN1). Both the overexpression of NOTCH1 or JAGGED1 separately
resulted in a moderate increase in NOTCH-dependent transcriptional
activity in these cells (Fig. 5A and B). However, co-expression of Jagged1
and Notch1 strongly activated NOTCH1 signaling, as compared with the
control (Fig. 5C). In all cases, the NOTCH-dependent transcriptional
activity could be decreased with the addition of soluble DLK1E-P or
DLK2E-P proteins to the cell culture media (Fig. 5B and C).
In an additional set of experiments, HEK 293T/17 cells, transiently
transfected with pGLucWT for 24 h, were seeded on culture plates
containing or not puriﬁed soluble DLL4E-P protein (Fig. 5D), anchored to
the bottom of the plates with an anti-HA antibody. These cells were
Fig. 3. DLK1 and DLK2 inhibit NOTCH signaling. A. Expression of Dlk1 and Dlk2 in Balb/c 14, 3T3-L1 cells, and Dlk1−/−MEFs, as determined by standard RT-PCR analysis. NOTCH1
signaling levels, as measured by luciferase assays, in Balb/c 14 (B), 3T3-L1 (C), and immortalized Dlk1−/−MEFS (D) transiently co-transfected with pGLucWT and pLNCX2 vectors
(control), or with pGLucWT and the pNIC-1 vectors. pNIC-1 expresses a constitutively active fragment of the intracellular region of human NOTCH1 (NICD1500). E. Analysis of the
NOTCH transcriptional activity in Balb/c14 cells transiently transfected with pGLucWT and pLNCX2-Myc-derived plasmids driving the expression of the extracelular DLK2 region
(Dlk2E) or the complete mRNA of Dlk2 in sense or antisense orientation (Dlk2 and Dlk2aS, respectively). (F) Analysis of NOTCH1 transcriptional activity in Balb/c 14 cells transiently
transfected with pGLucWT and plasmids driving the expression of different regions of DLK1. Dlk1, Dlk1E and Dlk1ΔP: complete cDNA of Dlk1, cDNA encoding for the extracellular
region of DLK1, and Dlk1 cDNA lacking the TACE protease target encoding region, respectively. The fold activation relative to the controls is presented as the average ± SD of at least
three separate experiments (Anova test: ** p ≤ 0.01, *** p ≤ 0.001).
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or puriﬁed DLK1E-P or DLK2E-P soluble proteins (Fig. 5E). We observed
that anchored DLL4E-Pwas able to activate endogenous NOTCH signaling
in these cells, and that soluble puriﬁedDLK1E-P orDLK2E-P proteinswere
able to reduce both the basal NOTCH signaling and the increase in NOTCH
activation triggered by anchoredDLL4E-P. Thus, these results suggest that
both DLK proteins compete with the ligands JAGGED1 and DLL4 for
NOTCH1 binding, leading to a decrease in NOTCH activity.
Finally, the potential effect of the DLK1/DLK2 protein interaction on
NOTCH activity was investigated by transfecting Balb/c 14, 3T3-L1, or
immortalized Dlk1−/− MEFs with the NOTCH-responsive reporter
construct and the two plasmids driving the expression of the entire
DLK1orDLK2proteins, separately or together (pCDLK1andpCDLK2). As
shown in Fig. 6A, B and C, DLK1 and DLK2 independently inhibited
endogenous NOTCH signaling in all cell lines studied. Surprisingly,endogenous NOTCH activationwas restored to normal levels in cells co-
expressing both DLK1 and DLK2 proteins. This result is compatible with
the formation of DLK1 and DLK2 heterodimers, as shown by the yeast
two-hybrid and co-immunoprecipitation assays, and may prevent the
interaction of the individual proteins with NOTCH1, thus allowing the
interaction of this receptorwith its canonical ligands leading to a greater
level of activation.
4. Discussion
This work demonstrates that the protein DLK2 interacts with itself,
withDLK1, anddespite of lacking aDSL domain, it interacts also, asDLK1
does, with the region of NOTCH1 involved in canonical ligand in-
teraction. The interaction of DLK proteins with themselves andwith the
NOTCH1 receptor, and their competitionwith the canonical ligands lead
Fig. 4. DLK1 and DLK2 modulate the proteolytic generation of the active intracellular domain of NOTCH1 in 3T3-L1 cells and MEFs. Representative Western blot analysis of active
NICD in 3T3-L1 cells transiently overexpressing DLK1 (pCDLK1 plasmid) (A), or DLK2 (pCDLK2 plasmid) (B) complete proteins. C. Representative Western blot analysis of active
NICD in wild type and Dlk1−/− MEFs. D. Representative Western blot analysis of active NICD in 3T3-L1 cells transiently transfected with pCN1, a plasmid expressing the entire
mouse NOTCH1 protein. E. Representative Western blot analysis of the active NICD in 3T3-L1 cells treated or not (DMSO) with the γ-secretase inhibitor DAPT for 48 h at 10 μM. The
active intracellular region of NOTCH1 (NICD) was detected by using the “Cleaved NOTCH1 (Val 1744)” antibody (Cell Signaling, Beverly, MA, USA), which speciﬁcally detects the
active NOTCH1 intracellular domain. DLK1 and DLK2 proteins were detected with the antibodies described in Material andMethods. Total NOTCH1 expression was detected with α-
NOTCH1 8 G10 (D) and α-NOTCH1 C20 (A, B, C and E) antibodies. Anti-α-tubulin antibody was used as the loading control. Vector: cells transfected with empty vectors.
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DLK2 interacts with itself, with DLK1 and with the NOTCH1 receptor in
the yeast two-hybrid system. The observed interactions are speciﬁc and
strong, sincemost yeast colonies co-expressing these proteins are able to
grow in a minimal medium containing high concentrations of 3-AT. In
addition, as it was previously demonstrated for DLK1, the interaction
betweenNOTCH1 andDLK2 appears to be speciﬁc for particular NOTCH1
regions, given that the two-hybrid assays showed that DLK2 does not
interact with the NOTCH1 EGF-like pairs 10–11 or 13–14, but it strongly
interacts with the EGF-like pair 12–13, which contains one of theNOTCH
EGF-like repeats (EGF12) shown to be the target for canonical ligand
binding [45,46,59–62]. Furthermore, the interaction of DLK2 with
NOTCH1 and the interaction of DLK1 with DLK2, detected by the yeast
two-hybrid system, have been conﬁrmed by co-immunoprecipitation
assays. However, in agreementwithwhatwas reported recently [63], we
could not detect the interaction of DLK1 with NOTCH1 by immunopre-
cipitation assays. Despite this, DLK1 interacts with NOTCH1 by the yeast
two-hybrid system, andmodulatesNOTCHactivity [15,26,30].We ignore
the reason why immunoprecipitation assays fail to detect the physical
interaction between DLK1 and NOTCH1 unveiled by the two-hybrid
system [26] (Fig.1), and supported by the results of the luciferase assays.
One possibility could be the different glycosylation levels or patterns of
NOTCH1 andDLK1 proteins inHEK293T/17 cells as compared to those of
yeast cells [58,62,64–68]. However, our data indicate that DLK2,
possessing much fewer potential glycosylation sites than DLK1,
immunoprecipitates with NOTCH1 even if differently glycosylated in
HEK 293T/17 cells. In any case, further studies are needed to explore the
interesting possibility that NOTCH1, DLK1 and DLK2 interactionsmay be
differently regulated depending upon distinct glycosylation patterns.
To study whether these newly detected protein interactions
could affect NOTCH signaling, we used a CBF1-dependent luciferasereporter gene in 3T3-L1 preadipocytes, Balb/c 14 cells and immortal-
ized Dlk1−/− MEFs. Our data indicate that, as DLK1 does, the DLK2
EGF-like extracellular region is involved in the negative regulation of
NOTCH activity. The decrease in the amount of active NOTCH1
intracellular region observed in 3T3-L1 cells expressing higher levels
of Dlk1 or Dlk2, and the increase of active NICD in Dlk1−/− MEFs, as
compared to wild type MEFs, conﬁrm the inhibitory effect of DLK
proteins on NOTCH activation and signaling. The inhibition of NOTCH1
activity in cells overexpressing DLK1 was stronger than that obtained
with DLK2, probably due to the lower overexpression of DLK2 in these
cells. Finally, DLK1 and DLK2 were able to inhibit DLL4 or JAGGED1-
triggered activation of NOTCH signaling. Taken together, these
studies demonstrate that both DLK1 and DLK2 independently act as
antagonists of NOTCH signaling.
The competition of soluble DLK proteins with NOTCH canonical
ligands argues in favor of the interaction of these proteins with the
same region of NOTCH1 as that the canonical ligands interact with.
This would prevent the interaction of the canonical ligands with this
speciﬁc receptor region, thus inhibiting NOTCH1 activation. However,
another possibility could be that DLK proteins interacted with
the ligands, thus preventing them to interact with their receptors.
However, we could not detect any interaction of NOTCH ligands with
DLK proteins.
Stoichiometrical relations between NOTCH receptors and their
ligands have been shown to be critical for the correct function of
these proteins in determining cell fates [49,69,70]. Previously pub-
lished results demonstrated that different Dlk1mRNA spliced variants
determine the production of membrane-associated or secreted DLK1
proteins with different effects on adipogenesis of 3T3-L1 cells [12,71–
77]. The idea that soluble andmembrane DLK1 variants exert different
functions is supported by the previous data that demonstrate that
Fig. 5.DLK1andDLK2competewithDLL4and JAGGED1canonical ligands tomodulateNOTCH1signaling.A.NOTCHtranscriptional activity inBalb/c14 cells transiently co-transfectedwith
pGLucWT and plasmids over-expressing the complete JAGGED1 or NOTCH1 proteins (pLPJ1 or pLPN1, respectively). B. NOTCH transcriptional activity in Balb/c14 cells transiently co-
transfectedwithpGLucWTandpLPJ1. These transfectedcellswere incubated in thepresenceofControl-P1,DLK1E-P, orDLK2E-P solublepuriﬁedproteins. C.NOTCH transcriptional activity
in Balb/c14 cells transiently transfectedwith pGLucWT, pLPJ1 andpLPN1plasmids. The cells transfectedwith the three plasmidswere incubated in thepresence of Control-P1, DLK1E-P, or
DLK2E-P soluble puriﬁedproteins. D.Westernblot analysis of soluble ligandDLL4 [DLL4E-P (DLL4E-6XHIS-HA)], puriﬁed fromculture supernatants ofHEK293T/17 transient transfectants.
Control-P1: puriﬁedculture supernatants fromHEK293T/17 cells transfectedwithpLPCX6HIS-HAempty vector. E. Analysis of theendogenousNOTCHtranscriptional activity inHEK293T/
17 cells transiently transfectedwith pGLucWT and seeded on culture plates containing the control puriﬁed sample (Control-P1) or puriﬁedDLL4E-P protein anchored to the bottomof the
platewith a-HAantibody. Cellswere also incubated in the presence of Control-P1, DLK1E-P, or DLK2E-P soluble puriﬁedproteins. Vector: empty vector. The fold activation is relative to the
controls, presented as the average±SD of at least three separate experiments (Anova test: *p≤0.05;**p≤0.01).
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would allow soluble DLK1 variants to inﬂuence DLK1–DLK1 mem-
brane interactions potentially important in cell communication [25].
The opposite effects of monomeric and dimeric DLK1 proteins on the
cellularity of thymus organ cultures also argue in favor of the different
functions of DLK1 variants [6].
Considering that the mechanism of NOTCH activation requires
mechanical stretching from the ligand to unprotect the NOTCHreceptors' proteolytic target region [47], one possibility to explain the
different activities of soluble andmembrane DLK1 proteinswas that the
secreted variants, unable to produce the necessary stretching,would act
as NOTCH inhibitors, whereas membrane bound DLK1 variants could
perhaps act as NOTCH activators. Recently, it has been demonstrated
that mammalian DLK1 is also able to inhibit NOTCH activation in
Drosophila [30], conﬁrming our results obtained with mouse cell lines



























































































Fig. 6. The interaction between DLK1 and DLK2 modulates NOTCH signaling. Analysis of the NOTCH activation levels in Balb/c 14 (A), 3T3-L1 (B), and immortalized Dlk1−/−MEFS
(C) co-transfected with pGLucWT and plasmids overexpressing DLK1 and/or DLK2 proteins. Vector: control cells transfected with empty vectors. The fold activation relative to the
controls is presented as the average±SD of at least three separate experiments (Anova test: * p≤0.05; ** p≤0.01).
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DLK1 region strongly inhibits NOTCH activity in the ﬂy. Data obtained
with mammalian cells that are presented in this work conﬁrm these
results. Amembrane-bound variant of DLK1, constructed to prevent the
action of the TACE protease that release the EGF-like region to the
extracellularmedium is, in fact, a strong inhibitor of NOTCH signaling in
Balb/c 14cells. Thesedata demonstrate thatboth soluble andmembrane
variants of DLK1 are able to inhibit NOTCH signaling. Recent data
demonstrate that DLK1 is necessary for proper skeletal muscle
development and regeneration, in a manner consistent with the notion
that DLK1 acts as an inhibitor for NOTCH signaling. NOTCH signaling is
known to inhibit MyoD expression and myogenic differentiation, but
enhances satellite cell proliferation and self-renewal. DLK1 conditional
mouse mutants showed elevated NOTCH signaling, and suppresed
MyoD expression. Conversely, over-expression of DLK1 suppressed
NOTCH signaling and promoted myogenic differentiation, but inhibit
myoblast proliferation [78].
Nevertheless, other authors have shown that DLK1 can activate
NOTCH signaling in C. elegans, as its co-activator OSM-11 does [79].
OSM-11 is a secreted protein and, therefore, it must team up with
other proteins located at the plasma membrane or the extracellular
matrix to produce the mechanical stretching necessary for NOTCH
activation. OSM-11 possesses a so-called DOS domain (also present at
the ﬁrst two EGF-like repeats of DLK1 and DLK2), which has been
reported to be involved in the interaction between OSM-11 and Lin-
12, one of the two C. elegansNOTCH homologs. Interestingly, our work
shows that the expression of DLK1 and DLK2 could favour NOTCH
activity in some contexts, in particular in the context of the co-
expression of both proteins. We observed that co-expression of DLK1
and DLK2, obtained by transfection of several cell types, resulted in a
recovering of NOTCH signaling, as compared to the NOTCH activity
obtained with the separate overexpression of DLK1 or DLK2. This
ﬁnding suggests that DLK1 and DLK2 may interact with each other
preventing the inhibition of NOTCH signaling. This might also be
happeningwith OSM-11 in C. elegans, given that this animal expresses
ﬁve DOS motif containing proteins [79–81]. Thus, the modulatory
effects of DLK proteins on NOTCH signaling are probably exerted incoordination by both DLK1 and DLK2. In this regard, nothing is known
yet about the potential processing of DLK2 to generate membrane and
soluble DLK2 variants inhibitory for NOTCH signaling, but its
structural and functional homologies with DLK1 suggest this
possibility. This, together with the potentially differential glycosyla-
tion of both proteins mentioned above, opens up several potential
ways for the regulation of NOTCH activity that need to be explored.
In summary, the data presented in this work suggest that the
interaction between both DLK proteins and their competition with the
canonical NOTCH ligands can modulate NOTCH activation and
signaling, which, in turn, may regulate the different cellular processes
where these proteins play a role, such as adipogenesis, among many
others. The vertebrate NOTCH/ligand system is very complex and
consists of several receptors and ligands. It is, therefore, possible that
the observed effects of DLK proteins on NOTCH signaling could
involve interactions not only with NOTCH1, as reported here, but also
with other NOTCH receptor and ligands. New studies are warranted to
establish the potential interactions of DLK proteins with other
members of the vertebrate NOTCH/ligand system leading to the
understanding of the action of DLK proteins on NOTCH function.
5. Conclusions
The following are the main conclusions of this work:
1. The extracellular region of the protein DLK2 interacts with the
extracellular region of DLK1 and with the EGF 10–15 region of
NOTCH1, which is one of the NOTCH1 regions binding to the ca-
nonical NOTCH ligands.
2. Both the extracellular DLK2 region and the entire DLK2 protein are
able to inhibit NOTCH activity in Balb/c 14 cells.
3. Similar to the soluble DLK1 EGF-like region and the entire DLK1
protein, a membrane variant of DLK1 lacking the extracellular
protease-sensitive region inhibits NOTCH signaling in Balb/c 14
cells.
4. The over-expression of DLK1 or DLK2 proteins in 3T3-L1 cells
results in lower levels of active NOTCH1 intracellular domain.
1163B. Sánchez-Solana et al. / Biochimica et Biophysica Acta 1813 (2011) 1153–11645. The amount of active NOTCH1 intracellular domain increases in
Dlk1−/− MEFs compared to wild type MEFs.
6. DLK1 and DLK2 soluble proteins, added to culture media, compete
with JAGGED1 and DLL4 canonical ligands for NOTCH receptor
binding.
7. The co-expresion of DLK1 and DLK2 results in higher levels of
NOTCH activity, suggesting that both proteins interact to modulate
NOTCH activity.
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